ChemicalBook > CAS DataBase List > Timigutuzumab
Timigutuzumab
- Product Name
- Timigutuzumab
- CAS No.
- 1665274-14-5
- Chemical Name
- Timigutuzumab
- Synonyms
- Timigutuzumab;Timigutuzumab (anti-ERBB2);Research Grade Timigutuzumab;Research Grade Timigutuzumab (DHC09605)
- CBNumber
- CB68081038
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Timigutuzumab Chemical Properties,Usage,Production
Uses
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer[1].
References
[1] Santis RD. Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. MAbs. 2020 Jan-Dec;12(1):1725346. DOI:10.1080/19420862.2020.1725346
Timigutuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Timigutuzumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9763
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
1665274-14-5, TimigutuzumabRelated Search:
Flanvotumab
Risankizumab
Nacolomabtafenatox
Birtamimab
Torudokimab
Dafsolimab
Cilgavimab
Enlimomab
Modotuximab
Suciraslimab